Intravitreal ranibizumab (Lucentis) for choroidal neovascularization associated with Stargardt’s disease

Abstract

Intravitreal ranibizumab injection seems to induce total regression of CNV complicating Stargardt's disease. Further investigations are required to confirm our results.

All That Glitters Are Not Flecks: Inflammatory Choroidal Neovascularization in Fundus Flavimaculatus

“…CNV in FFM is extremely rare, with handful of reports documenting successful outcomes with photodynamic therapy 3 or intravitreal ranibizumab injections. 4 Similar to previous reports, our case had complete resolution of CNV with IVB. Bevacizumab (Avastin; Genentech, San Francisco, CA, USA) is a full-length humanized antibody that binds to all types of VEGF.…”

“…2 Choroidal neovascularization (CNV) is a rare complication in FFM, with handful of cases reported in literature so far. 3,4 Here we report a case of inflammatory CNV in FFM.…”

Type 3 Choroidal Neovascularization Associated with Fundus Flavimaculatus

“…Retinal angiomatous proliferation or type 3 CNV can be considered as a subtype of CNV, be- ing in the spectrum of neovascular age-related macular degeneration, and is characterized by a particularly poor prognosis. Ranibizumab (Lucentis; Genentech) is a recombinant, humanized, monoclonal antibody antigen-binding fragment that neutralizes all biologically active forms of vascular endothelial growth factor, effectively used in the treatment of exudative age-related macular degeneration, as well as in the treatment of type 3 CNV [6] and of CNV associated with Stargardt's disease [7] .…”

Trial Interventions in ABCA4- Retinopathy

“…STGD disease course is progressive central atrophy and therefore, the loss of central visual capacity [46]. Choroidal neovascularisation (CNV) associated with STGD is uncommon, but it may lead to a further deterioration of visual acuity.…”

“…It may develop as a natural course of the disease or due to trauma to Bruch's membrane during the surgical procedure associated with previous surgical treatment options. Because the CNV growth is rare, which uncommonly can complicate ABCA4 retinopathy, there is a restrict data availability of its management options [46,47]. There are many possibilities which are currently widely used as intravitreal injection IVI, including aflibercept (Eylea), ranibizumab (Lucentis), and bevacizumab (Avastin).…”